Interleukin-6 is not essential for bone turnover in hypothyroid mice

Folia Histochemica et Cytobiologica

Volumn 45, Issue 4, 2007, Pages 387-392

  Mysliwiec, Janusz ^a   Zbucki, Robert ^a   Winnicka, Maria M ^a   Sawicki, Boguslaw ^a   Nikolajuk, Agnieszka ^a   Kaminski, Karol ^a   Mysliwiec, Piotr ^a   Musial, Wlodzimierz ^a   Bondyra, Zofia ^a   Walecki, Jerzy ^a   Gorska, Maria ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone turnover; Hypothyroidism; IL 6; IL 6 knockout mice

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; INTERLEUKIN 6; OSTEOCALCIN; PROPYLTHIOURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; C57BL 6 MOUSE; CONTROLLED STUDY; EUTHYROIDISM; FEMALE; HYPOTHYROIDISM; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OSSIFICATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; THYROID GLAND; WILD TYPE;

ANIMALIA; MUS;

EID: 38849147011     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Roodman GD. Interleukin-6: an osteotropic factor? J Bone Miner Res. 1992;7:475-478.
2. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999;25: 255-259.
3. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NE-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002; 169:3353-3362.
4. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339-342.
5. Kawasaki K, Gao YH, Yokose S, Kaji Y, Nakamura T, Suda T, Yoshida K, Taga T, Kishimoto T, Kataoka H, Yuasa T, Norimatsu H, Yamaguchi A. Osteoclasts are present in gp130-deficient mice. Endocrinology. 1997;138:4959-4965.
6. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13:1189-1196.
7. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. QJM. 2002;95:233-240.
8. Verdelli D, Mattioli M, Fabris S, Nobili L, Intini D, Guerneri S, Todoerti K, Zanella A, Deliliers GL, Lombardi L, Neri A. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. Haematologica. 2005;90:1541-1548.
9. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, Bryant-Greenwood G, Jones SA. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54:2084-2095.
10. Steddon SJ, McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant. 2004;19:3078-3083.
11. Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci USA. 2002;12:14728-14733
12. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation and bone loss in mice. Am J Physiol Endocrinol Metab. 2005;289: E784-E793.
13. Mysliwiec J, Zbucki R, Winnicka MM, Sawicki B, Nikolajuk A, Kaminski K, Mysliwiec P, Musial W, Bondyra Z, Walecki J, Gorska M. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice. Hormon Metab Res (in press).
14. Williams GR, Bland R, Sheppard MC. Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. Endocrinology. 1994;135: 2375-2385.
15. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med. 1995; 332:305-311.
16. Pereira RC, Jorgetti V, Canalis E. Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts. Am J Physiol Endocrinol Metab. 1999;277:E496-E504.
17. Stevens DA, Harvey CB, Scott AJ, O'Shea PJ, Barnard JC, Williams AJ, Brady G, Samarut J, Chassande O, Williams GR. Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone. Mol Endocrinol. 2003;17:1751-1766.
18. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab. 1999;84:435-439.
19. Siddiqi A, Burrin JM, Wood DF, Monson JP. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells. J Endocrinol. 1998;157:453-461.
20. Kim CH, Kim HK, Shong YK. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss. J Endocrinol. 1999;160:97-102.
21. Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int. 2004;15:209-216.
22. Hallen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaannen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000; 15:1337-1345.
23. Marshall K, Nash K, Haussman G, Cassady I, Hume D, de Jersey J, Hamilton S. Recombinant human and mouse purple acid phosphatases: expression and characterization. Arch Biochem Biophys. 1997;345:230-236.
24. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-?B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem. 1999;274:19301-19308.
25. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda TRegulation of Matrix Metalloproteinases (MMP-2, -3, -9, and -13) by Interleukin-1 and Interleukin-6 in Mouse Calvaria: Association of MMP Induction with Bone Resorption. Endocrinology. 1998;139:1338-1345.
26. Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf). 2002;57:125-129.
27. Varga F, Spitzer S, Rumpler M, Klaushofer K. 1,25-Dihydroxyvitamin D3 inhibits thyroid hormone-induced osteocalcin expression in mouse osteoblast-like cells via a thyroid hormone response element. J Mol Endocrinol. 2003;30:49-57.
28. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002;298: 843-846.